Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study

Table 1 Demographic data of study and normal population

	Cholelithiasis group n = 7938		Control group n = 23814		P value
	N	SD, %	N	SD, %
Age, mean (SD)	59.15	16.53	59.15	16.53	1
Age, yr
18-49	38.89	7.38	38.94	7.38
50-69	59.13	5.52	59.13	5.52
> 70	78.67	5.95	78.67	5.95
Gender					1
Male	3798	47.85	11394	47.85
Female	4140	52.15	12420	52.15
Follow up time (mo), mean (SD)	57.96	21.48	63.12	15.6	< 0.001
Economic status					< 0.001
MBS	3963	49.92	11216	47.1
1-3 times MBS	3136	39.51	10217	42.9
Above 3 times MBS	825	10.39	2336	9.81
Place of residence					0.007
City	5046	63.57	15078	63.32
Countryside	2747	34.61	8403	35.29
Remote village	131	1.65	287	1.21
Comorbidity
CHB	754	9.5	667	2.8	< 0.001
CHC	542	6.83	474	1.99	< 0.001
HP	128	1.61	131	0.55	< 0.001
DM	2319	29.21	4327	18.17	< 0.001
ESRD	186	2.34	357	1.5	< 0.001
CCDL	51	0.64	7	0.03	< 0.001
CO	0	0	0	0	NA
IBD	119	1.5	184	0.77	< 0.001
Cholangiocarcinoma
Number (rate)	147	1.85	39	0.16	< 0.001
Follow up time (mo), mean (SD)	13.92	21.96	31.8	21.48	< 0.001
Cholangiocarcinoma after first 6 mo
Number (rate)	55	0.69	35	0.15	< 0.001
Follow up time (mo), mean (SD)	36.73	20.57	35.27	19.94	0.86

SD: Standard deviation; MBS: Minimum basic salary; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; HP: Helicobacter infection; DM: Diabetes mellitus; ESRD: End-stage renal disease; CCDL: Congenital cystic disease of liver; CO: Clonorchis Opisthorchis; IBD: Inflammatory bowel disease.